- Home
- / Kee Song Bio-Technology Holdings
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Kee Song Bio-Technology Holdings financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
NT$2.6 B
FY, 2022
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| TWD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|
| Revenue | 2.8B | 3.0B | 2.5B | 2.3B | 2.6B |
| Cost of goods sold | 2.4B | 2.5B | 2.0B | 1.7B | 2.0B |
| Gross profit | 439.8M | 517.6M | 554.6M | 628.2M | 614.4M |
| Gross profit margin, % | 17.0% | 21.8% | 27.4% | 23.9% | |
| Operating expense total | 416.2M | 454.4M | 380.9M | 383.3M | 376.6M |
| Depreciation and amortization | 104.3M | 168.5M | 149.2M | 128.5M | 122.2M |
| EBITDA | 23.6M | 58.6M | 169.5M | 237.6M | 214.9M |
| EBITDA margin, % | 1.9% | 6.7% | 10.4% | 8.4% | |
| EBIT | (130.5M) | (91.4M) | 45.6M | 116.5M | 178.1M |
| EBIT margin, % | -3.0% | 1.8% | 5.1% | 6.9% | |
| Interest income | 4.4M | 4.3M | 2.2M | 1.3M | 3.0M |
| Interest expense | 41.1M | 54.8M | 47.6M | 38.9M | 26.1M |
| Pre tax profit | (163.9M) | (163.3M) | (10.8M) | 80.2M | 150.7M |
| Income tax expense | (8.4M) | (324.0K) | 24.9M | 1.1M | 56.0M |
| Net Income | (155.4M) | (163.0M) | (35.8M) | 79.1M | 94.6M |